New inhaled drug for lung scarring passes early safety tests
NCT ID NCT06746064
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-stage study tested an inhaled drug called CHF10073 in 155 healthy volunteers to see if it is safe and how the body processes it. The study also checked how another drug, itraconazole, affects CHF10073 levels. The goal was to gather safety information before testing the drug in people with pulmonary fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
SGS Belgium NV Clinical Pharmacology Unit
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.